A recent clinical study stated that Montelukast is effective for reducing wheezing score and reduced the need for inhaled β2 agonist medication in the first weeks of a recurrent wheezing illness for children 3 -36 months of age. The study was published in the Pediatric allergy and immunology journal . Nearly one out of three children experience at least one wheezing episode, a common lower airway symptom, during a respiratory tract infection during the first three years of life. Generally, cysteinyl-leukotrienes are increased in the airways of infants with virus-associated wheezing.
Study details The study is a double-blinded randomized controlled trial which included children aged 3-36 months with wheezing illness, diagnosed by the physician. The children were randomized to receive either 4-mg Montelukast or placebo in the tablet form once in the evening for 56 days. A symptom score…
